PHILADELPHIA — (Feb. 11, 2019) — The Wistar Institute announces that it was awarded more than $16M in federal research funds in support of its groundbreaking research in cancer, immunology and infect…
PHILADELPHIA — (Feb. 7, 2019) — A novel, synthetic DNA vaccine developed at The Wistar Institute induces protective immunity against Mayaro virus (MAYV), a mosquito-borne infection endemic to South A…
CAMBRIDGE, MA and PHILADELPHIA — January 30, 2019 — Cullinan Oncology, LLC and The Wistar Institute today announced an agreement to accelerate the development of VK-2019, a novel EBNA1 (Epstein-Barr…
PHILADELPHIA — (Jan. 24, 2019) — Wistar scientists and collaborators demonstrated the utility of an optimized synthetic DNA vaccine platform for rapidly inducing immunity against unique combinations…
PHILADELPHIA — (January 8, 2019) — The Wistar Institute, along with partners Penn Medicine and Inovio Pharmaceuticals, Inc. (NASDAQ:INO), announce that the FDA has approved the initiation of a first-…
PHILADELPHIA — (Dec. 13, 2018) — Are we looking at the masked exoskeleton of cinema’s latest superhero, a firework and an amoeba? No, these images are the eye of a beetle, the central region of the r…
PHILADELPHIA — (Nov. 15, 2018) — Researchers at The Wistar Institute have developed novel synthetic DNA-encoded monoclonal antibodies (DMAbs) directed against PCSK9, a protein key to regulating chole…
PHILADELPHIA — (Nov. 13, 2018) — Scientists at The Wistar Institute and collaborators have successfully engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that were…
PHILADELPHIA — (Nov. 13, 2018) — According to new research from The Wistar Institute, the S100A14 protein is expressed at higher levels in people who inject drugs and remain uninfected despite many y…
PHILADELPHIA — (Oct. 15, 2018) — Researchers at The Wistar Institute have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing tha…
